Drug pipeline
Full profile accessExplore the programs pursuing this target and their development progress.
- Drug candidates
- Developers
- Development stage
Target intelligence / Profile preview
The carnitine shuttle pathway is an essential metabolic system composed of enzymes and transporters that facilitate the import of long-chain fatty acids into the mitochondrial matrix for β-oxidation. The core components include carnitine palmitoyltransferase 1 (CPT1, in the outer mitochondrial membrane), carnitine-acylcarnitine translocase (CACT, encoded by SLC25A20, in the inner mitochondrial membrane), and carnitine palmitoyltransferase 2 (CPT2, in the inner mitochondrial membrane)[1][2][3][6]. Additionally, the plasma membrane transporter OCTN2 (SLC22A5) is responsible for carnitine uptake into cells[3]. Defects in any of these proteins disrupt fatty acid oxidation and energy homeostasis, resulting in metabolic diseases, cardiomyopathy, and muscle weakness. Some pharmacological agents target CPT1 or the carnitine shuttle to manipulate energy metabolism in heart disease or cancer research.
Inhibition of carnitine palmitoyltransferase 1 (CPT1) to reduce fatty acid oxidation Supplementation with L-carnitine to restore or enhance fatty acid transport
2 more in the full profile.
Beyond the preview
Explore the evidence, development activity, and competitive landscape with Gosset’s full data platform.
Explore the programs pursuing this target and their development progress.
Follow the clinical studies evaluating therapies directed at this target.
Compare approaches across drug candidates, modalities, and indications.
Investigate the research and source evidence behind target biology and development.
Explore patent activity around therapies and technologies addressing this target.
Connect target biology, drug development, and emerging evidence in your research.
See how Gosset can support your research on Carnitine shuttle pathway enzymes and transporters.